LBH589

Known as: (2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide, LBH 589, NVP-LBH589 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2018
010203020042018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
LBH589 is a novel pan-histone deacetylase (HDAC) inhibitor that has potent antitumor activity in multiple myeloma and other… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
Despite the significant progress made in colon cancer chemotherapy, advanced disease remains largely incurable and novel… (More)
  • table 1
  • table 1
  • table 2
  • table 2
  • table 3
Is this relevant?
2007
2007
Activating mutations in the epidermal growth factor receptor (EGFR) selectively activate signal transducers and activators of… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Multiple myeloma represents an incurable disease, for which development of new therapies is required. Here, we report the effect… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE Angiogenesis is required for tumor progression and represents a rational target for therapeutic intervention. Histone… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In… (More)
  • table 2
  • figure 1
  • figure 2
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Histone deacetylase (HDAC) inhibitors have shown cytotoxicity as single agents in preclinical studies for multiple myeloma (MM… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Histone deacetylases (HDAC) have been identified as therapeutic targets due to their regulatory function in DNA structure and… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Present studies show that LBH589, a novel cinnamic hydroxamic acid analog histone deacetylase inhibitor, induces acetylation of… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The hydroxamic acid (HAA) analogue pan-histone deacetylase (HDAC) inhibitors (HDIs) LAQ824 and LBH589 have been shown to induce… (More)
Is this relevant?